These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9373324)

  • 41. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV-2 neutralization by intact V3-specific Fab fragments.
    Sourial S; Nilsson C
    Virol J; 2008 Aug; 5():96. PubMed ID: 18706111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
    Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
    J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies.
    Sharon M; Görlach M; Levy R; Hayek Y; Anglister J
    Protein Expr Purif; 2002 Apr; 24(3):374-83. PubMed ID: 11922753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
    Glamann J; Burton DR; Parren PW; Ditzel HJ; Kent KA; Arnold C; Montefiori D; Hirsch VM
    J Virol; 1998 Jan; 72(1):585-92. PubMed ID: 9420262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3-specific and non-V3-specific antibodies.
    Rencher SD; Hurwitz JL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):69-73. PubMed ID: 9358100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crystallization, sequence, and preliminary crystallographic data for an antipeptide Fab 50.1 and peptide complexes with the principal neutralizing determinant of HIV-1 gp120.
    Stura EA; Stanfield RL; Fieser GG; Silver S; Roguska M; Hincapie LM; Simmerman HK; Profy AT; Wilson IA
    Proteins; 1992 Dec; 14(4):499-508. PubMed ID: 1438187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer.
    Li L; Wang XH; Banerjee S; Volsky B; Williams C; Moody MA; Zolla-Pazner S; Gorny MK
    Hum Antibodies; 2012; 21(3-4):65-73. PubMed ID: 23549023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    Moore JP; McCutchan FE; Poon SW; Mascola J; Liu J; Cao Y; Ho DD
    J Virol; 1994 Dec; 68(12):8350-64. PubMed ID: 7525988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
    Kliks SC; Shioda T; Haigwood NL; Levy JA
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11518-22. PubMed ID: 7505441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
    Haldar B; Burda S; Williams C; Heyndrickx L; Vanham G; Gorny MK; Nyambi P
    PLoS One; 2011 Feb; 6(2):e17253. PubMed ID: 21383841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.
    Ghiara JB; Ferguson DC; Satterthwait AC; Dyson HJ; Wilson IA
    J Mol Biol; 1997 Feb; 266(1):31-9. PubMed ID: 9054968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120.
    Killikelly A; Zhang HT; Spurrier B; Williams C; Gorny MK; Zolla-Pazner S; Kong XP
    Biochemistry; 2013 Sep; 52(36):6249-57. PubMed ID: 23944979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.